# A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis

> **NCT01576887** · PHASE2 · WITHDRAWN · sponsor: **Biogen**

## Conditions studied

- End-Stage Renal Disease
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Bardoxolone Methyl 20 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01576887
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-07-31
- **Primary completion:** 2012-10-31
- **Final completion:** 2012-10-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** IDMC recommendation for safety concerns
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01576887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01576887, "A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01576887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*